Most bought healthcare stocks in Q3 2024
See which Healthcare stocks institutional investors increased the most in Q3 2024, measured as net growth in reported share positions from Q2 2024 into Q3 2024. Notable additions at the top of this list include BAXTER INTERNATIONAL INC (BAX), TEVA PHARMACEUTICAL-SP ADR (TEVA), RECURSION PHARMACEUTICALS-A (RXRX), AVANTOR INC (AVTR). These rankings aggregate SEC 13F filings from all institutional investors in our database.
Explore more:
| Symbol | Name | Net shares | Net value | New | Added | Trimmed | Sold out | Holding now |
|---|---|---|---|---|---|---|---|---|
| BAX | BAXTER INTERNATIONAL INC | 18,453,544 | $977.30M | 2 | 8 | 3 | 0 | 14 |
| TEVA | TEVA PHARMACEUTICAL-SP ADR | 6,143,847 | $139.00M | 1 | 2 | 4 | 0 | 8 |
| RXRX | RECURSION PHARMACEUTICALS-A | 4,628,268 | $4.86M | 0 | 2 | 0 | 0 | 3 |
| AVTR | AVANTOR INC | 4,062,947 | $473.33M | 1 | 4 | 5 | 0 | 12 |
| CVS | CVS HEALTH CORP | 3,950,772 | $554.64M | 3 | 7 | 10 | 1 | 21 |
| BMRN | BIOMARIN PHARMACEUTICAL INC | 2,951,234 | -$48.05M | 1 | 3 | 4 | 1 | 8 |
| OPCH | OPTION CARE HEALTH INC | 2,424,147 | $77.37M | 2 | 2 | 1 | 0 | 5 |
| PRVA | PRIVIA HEALTH GROUP INC | 2,291,448 | $49.35M | 1 | 3 | 0 | 0 | 4 |
| SYK | STRYKER CORP | 2,060,689 | $947.18M | 3 | 7 | 6 | 0 | 18 |
| TEM | TEMPUS AI INC | 1,855,459 | $116.31M | 0 | 1 | 0 | 0 | 1 |
| ELEV | ELEVATION ONCOLOGY INC | 1,785,982 | $1.07M | 1 | 0 | 0 | 0 | 1 |
| SOLV | SOLVENTUM CORP | 1,771,557 | $216.93M | 1 | 3 | 3 | 2 | 9 |
| DOCS | DOXIMITY INC-CLASS A | 1,523,807 | $191.54M | 1 | 2 | 1 | 1 | 4 |
| GH | GUARDANT HEALTH INC | 1,507,557 | $31.88M | 2 | 2 | 0 | 0 | 4 |
| NVST | ENVISTA HOLDINGS CORP | 1,465,983 | $70.59M | 1 | 2 | 3 | 0 | 6 |
| ALHC | ALIGNMENT HEALTHCARE INC | 1,464,579 | $39.50M | 0 | 1 | 1 | 0 | 2 |
| WRBY | WARBY PARKER INC-CLASS A | 1,423,134 | $25.64M | 0 | 3 | 1 | 0 | 4 |
| BSX | BOSTON SCIENTIFIC CORP | 1,342,301 | $136.75M | 4 | 6 | 3 | 0 | 14 |
| VREX | VAREX IMAGING CORP | 1,278,739 | $6.34M | 0 | 2 | 2 | 0 | 4 |
| TXG | 10X GENOMICS INC-CLASS A | 1,241,416 | $57.91M | 0 | 2 | 1 | 1 | 4 |
| ABCL | ABCELLERA BIOLOGICS INC | 1,218,100 | $2.54M | 0 | 1 | 0 | 0 | 1 |
| CLOV | CLOVER HEALTH INVESTMENTS CO | 1,207,600 | $21.33M | 0 | 1 | 0 | 0 | 3 |
| XRAY | DENTSPLY SIRONA INC | 1,188,116 | $61.73M | 1 | 4 | 0 | 0 | 6 |
| MRK | MERCK & CO. INC. | 1,078,855 | $53.31M | 1 | 7 | 11 | 5 | 25 |
| ADMA | ADMA BIOLOGICS INC | 1,046,747 | $44.68M | 0 | 1 | 1 | 0 | 2 |
| NVAX | NOVAVAX INC | 957,407 | $12.06M | 1 | 3 | 1 | 0 | 5 |
| BMY | BRISTOL-MYERS SQUIBB CO | 907,910 | $429.94M | 2 | 10 | 9 | 1 | 22 |
| ASRT | ASSERTIO HOLDINGS INC | 856,309 | $867.79K | 0 | 1 | 0 | 0 | 1 |
| ABSI | ABSCI CORP | 833,734 | $7.26M | 0 | 1 | 0 | 0 | 1 |
| MYGN | MYRIAD GENETICS INC | 805,481 | $28.18M | 1 | 1 | 0 | 0 | 2 |
| BDX | BECTON DICKINSON AND CO | 797,309 | $219.82M | 2 | 8 | 3 | 0 | 16 |
| BAYRY | BAYER AG-SPONSORED ADR | 785,085 | $12.91M | 0 | 1 | 0 | 0 | 1 |
| HUM | HUMANA INC | 774,517 | -$197.07M | 0 | 8 | 1 | 2 | 9 |
| FGEN | FIBROGEN INC | 753,140 | $300.80K | 1 | 0 | 0 | 0 | 1 |
| SGMO | SANGAMO THERAPEUTICS INC | 726,200 | $2.72M | 0 | 1 | 0 | 0 | 1 |
| CNC | CENTENE CORP | 658,806 | $71.10M | 3 | 2 | 4 | 0 | 9 |
| OGN | ORGANON & CO | 650,699 | $1.99M | 2 | 5 | 1 | 0 | 9 |
| MNKD | MANNKIND CORP | 637,920 | $4.20M | 0 | 1 | 1 | 0 | 3 |
| PSNL | PERSONALIS INC | 625,437 | $34.48M | 0 | 1 | 1 | 0 | 2 |
| NTLA | INTELLIA THERAPEUTICS INC | 624,296 | -$8.46M | 0 | 2 | 1 | 1 | 3 |
| TALK | TALKSPACE INC | 561,600 | $866.93K | 1 | 1 | 0 | 0 | 2 |
| NTRA | NATERA INC | 521,621 | $78.53M | 1 | 6 | 0 | 0 | 7 |
| KZR | KEZAR LIFE SCIENCES INC | 518,600 | $535.81K | 0 | 1 | 0 | 0 | 1 |
| NVRO | NEVRO CORP | 505,819 | -$3.55M | 0 | 1 | 1 | 0 | 2 |
| HCA | HCA HEALTHCARE INC | 497,240 | $657.04M | 3 | 5 | 4 | 1 | 12 |
| CPRX | CATALYST PHARMACEUTICALS INC | 485,908 | $19.22M | 1 | 2 | 0 | 0 | 3 |
| KPTI | KARYOPHARM THERAPEUTICS INC | 485,180 | $374.26K | 0 | 1 | 0 | 0 | 1 |
| AUPH | AURINIA PHARMACEUTICALS INC | 466,313 | $4.92M | 0 | 2 | 1 | 0 | 4 |
| BLUE | BLUEBIRD BIO INC | 451,168 | -$230.56K | 0 | 2 | 1 | 0 | 4 |
| ACRS | ACLARIS THERAPEUTICS INC | 448,500 | $562.61K | 0 | 1 | 0 | 0 | 2 |
Frequently asked questions about Most bought healthcare stocks in Q3 2024
What are the most bought Healthcare stocks in Q3 2024?
The most bought healthcare stocks in Q3 2024 are those with the largest increase in reported share counts across institutional investors compared to Q2 2024, based on SEC 13F filings.
Which healthcare stocks did institutional investors added to the most in Q3 2024?
Among filers in this sector, net additions were largest in companies such as BAXTER INTERNATIONAL INC (BAX), TEVA PHARMACEUTICAL-SP ADR (TEVA), RECURSION PHARMACEUTICALS-A (RXRX), based on aggregated 13F data.
How is institutional buying calculated?
Buying is calculated by summing the net increase in shares reported by institutional investors between two consecutive quarterly 13F snapshots (compared to Q2 2024).
Does this include all institutional owners?
Yes. These rankings aggregate SEC 13F filings from all institutional investors in our database, not only the investors we track individually.
Are these trades real-time?
No. 13F filings are reported quarterly and may be delayed by up to 45 days. The data reflects positions at the end of the reporting period, not real-time trading activity.